Drug development company RegeneRx Biopharmaceuticals (Other OTC:RGRX) reported on Monday the receipt of the notice of acceptance for a patent from the Australian Patent Office for the use of Thymosin beta 4 (T?4) in patients with neural injury and disease.
"In our study we stimulate resident (epicardial) progenitor cells, which are already in the right environment and poised to respond to the injury signals once activated by Thymosin B4."
(San Mateo, CA; 650-358-3456) announced that the European Patent Office has granted a use patent for the use of thymosin alpha 1 as a treatment for hepatitis C as a monotherapy or in combination with interferon.
Drug company RegeneRx Biopharmaceuticals (Other OTC:RGRX) reported on Friday the receipt of notice of Intent to Grant a patent from the European Patent Office for the treatment of neural injury using Thymosin beta 4 (T?4) in the EU.